21 septiembre 2015
Bretuximab vedotin is an effective and safe first course of treatment for older Hodgkin lymphoma patients unfit for chemotherapy, a new report suggests. While standard chemotherapy can achieve complete remissions in younger Hodgkin lymphoma patients, the majority of those 60 and older are either ineligible or refuse treatment in order to avoid complications related to drug toxicity.
http://www.sciencedaily.com/releases/2015/09/150921151434.htm
